Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy - Wikidata - wikimedia - TriplyDB

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

http://www.wikidata.org/entity/Q35200424

about

Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series."Liquid elbows" due to afatinib administration.Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.A new mode of ventilation for interventional pulmonology. A case with EBUS-TBNA and debulking.

P2860

Q33763622-E4E585A2-78E2-4364-951F-8706261BD3D6 Q33855130-53E50B5D-640B-4367-9F3D-2C6F1A99640F Q37033793-6F57C03E-C2D7-443B-90BC-939B6893A12E Q37347532-57B8F858-9D05-43E7-8C4C-102752C8ECDA Q38905885-DD5F8CEA-A99F-44BC-840D-E1C442EA8DCB Q41072491-E3B12F2F-5081-446C-A7CE-D58C2689BF96 Q41107790-53D628FC-09D6-49D1-96EC-CFFD7E7EB798 Q47105617-984841D0-2C6C-4CA1-AE83-301187ED8767 Q47138288-5F6C1ABE-ED0D-4BCD-AEAF-3CA5CCF49EE5 Q47682234-1AEEFDAB-028B-4E19-A459-BD289BF1D16E

P2860

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

http://www.wikidata.org/entity/Q35200424

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

@ast

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

@en

type

label

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

@ast

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

@en

prefLabel

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

@ast

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

@en

P1433

Q35200424-14133327-6702-4AA9-B956-B28632BE1B28

P1476

Q35200424-1278E981-4B1B-4F44-8281-4D2CC2B5BA0C

P2093

Q35200424-4F4F00DD-DD27-4F65-896D-5233308351F5

Q35200424-AFE9597A-A6AB-4039-B5D3-B60E1097C244

Q35200424-CAD9FAAB-8803-4FBB-AEF0-9D334EA3AD86

Q35200424-F4872162-DBEA-4695-A87C-3AE1A0784B6A

P2860

Q35200424-066E647A-2511-498E-80FC-6B2DA6FFCC4E

Q35200424-0A9BE8B7-A022-4D1C-B8DA-B4853979B3A2

Q35200424-0A9E0449-D704-4BED-9799-77387CE3756B

Q35200424-1133E650-78FF-48B5-811C-2FA1D44CC556

Q35200424-19C8A1B6-A2DC-48D7-A1B9-27A6EC58BC3C

Q35200424-1B699DCF-BCB2-405C-A6A6-19DAF3016F98

Q35200424-1F720F48-DC52-4DC8-9BBC-F6210C09D5F2

Q35200424-398F6BCD-F0A9-4287-99F5-427D901AE7C2

Q35200424-48C0CB08-D254-4165-949D-D1F86B697F53

Q35200424-51F1760B-AB3D-4B80-BCE4-10AE70EBC916

P304

Q35200424-38B6B580-F8BE-42CD-BB8F-73F4CD4966F8

P31

Q35200424-7e61ec77-2b81-4b41-a934-942c17e8f026

Q35200424-F80A8682-59C2-45CE-8F56-007A67E32841

P356

Q35200424-25807781-6EF3-49E9-8B33-88FDA55B9964

P433

Q35200424-E92573C8-6E5F-47BB-922B-E6FA36AC8B49

P478

Q35200424-C5144BA1-2154-4C13-8B9C-0A97D6939061

P577

Q35200424-7B0730E2-776F-4644-A8A5-5FD41AEE7FC2

P698

Q35200424-FA7E9B3A-E66D-4138-B82B-F6FCC4BA9A4E

P921

Q35200424-0CAEC77F-AA13-4C11-926A-7D91BAAEC2FD

P932

Q35200424-97D9ED60-B47A-4C94-B7CF-7512519102E5

P356

J.ISSN.2218-6751.2012.12.06

P1433

Translational lung cancer research

P1476

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy

@en

P2093

Kaid Darwiche

http://www.w3.org/2001/XMLSchema#string

Kalliopi Domvri

http://www.w3.org/2001/XMLSchema#string

Konstantinos Zarogoulidis

http://www.w3.org/2001/XMLSchema#string

Paul Zarogoulidis

http://www.w3.org/2001/XMLSchema#string

P2860

The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

Cancer statistics, 2010

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.

Multidisciplinary management of lung cancer.

Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.

P304

256-258

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2218-6751.2012.12.06

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25806240

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

4367615

http://www.w3.org/2001/XMLSchema#string